HOUSTON, Feb. 8, 2024
/PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics"), a
clinical-stage biotechnology company focused on the development of
therapeutics and potential cures for chronic diseases using
fibroblasts and fibroblast-derived materials, announced the
issuance of three patents from the United States Patent Office
(USPTO) to add to its portfolio.
Issued Patents:
- Patent 11,717,596 (Inventor: Lionel Sevrain) METHODS AND
COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO
BIOREACTOR
- Patent 11,732,239 (Inventor: Pete
O'Heeron) TREATMENT OF DISC DEGENERATIVE DISEASE AND
STIMULATION OF PROTEOGLYCAN SYNTHESIS BY FIBROBLAST CONDITIONED
MEDIA AND FORMULATION THEREOF
- Patent 11,819,555 (Inventor: Pete O'Heeron) GENE THERAPY
FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS
"As we develop our science, these new patents add to our
extensive portfolio of 150+ patents issued and pending, which
validate the uniqueness of our potential treatments and processes,"
said Pete O'Heeron, Chief Executive
Officer of FibroBiologics. "The United
States is the largest market for our three product
candidates and we are continually striving to add additional
protections for our technology."
For more information, please visit FibroBiologics'
website or email FibroBiologics at:
info@fibrobiologics.com.
Cautionary Statement Regarding Forward-Looking
Statements
This communication may contain "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include information concerning
FibroBiologics' possible or assumed future results of operations,
business strategies, debt levels, competitive position, industry
environment, potential growth opportunities and the effects of
regulation, including whether FibroBiologics will generate returns
for stockholders. These forward-looking statements are based on
FibroBiologics' management's current expectations, estimates,
projections and beliefs, as well as a number of assumptions
concerning future events. When used in this communication, the
words "estimates," "projected," "expects," "anticipates,"
"forecasts," "plans," "intends," "believes," "seeks," "may,"
"will," "should," "future," "propose" and variations of these words
or similar expressions (or the negative versions of such words or
expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future
performance, conditions or results, and involve a number of known
and unknown risks, uncertainties, assumptions and other important
factors, many of which are outside FibroBiologics' management's
control, that could cause actual results to differ materially from
the results discussed in the forward-looking statements, including
those set forth in the Risk Factors section of FibroBiologics'
Registration Statement for the Direct Offering filed with the SEC.
Copies are available on the SEC's website, www.sec.gov. These
risks, uncertainties, assumptions and other important factors
include, but are not limited to: (a) the occurrence of any event,
change or other circumstances that could cause the Registration
Statement to not become effective; (b) the ability of
FibroBiologics to continue to meet Nasdaq listing requirements; (c)
the ability to effectively manage the business as a result of the
super-voting proxy given to the Board of Directors. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and FibroBiologics assumes no obligation and, except as required by
law, does not intend to update or revise these forward-looking
statements, whether as a result of new information, future events,
or otherwise. FibroBiologics gives no assurance that it will
achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a cell therapy,
regenerative medicine company developing a pipeline of treatments
and potential cures for chronic diseases using fibroblast cells and
fibroblast-derived materials. FibroBiologics holds 150+ US and
internationally issued patents/patents pending across various
clinical pathways, including disc degeneration, orthopedics,
multiple sclerosis, psoriasis, wound healing, reversing organ
involution, and cancer. FibroBiologics represents the next
generation of medical advancement in cell therapy. For more
information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic
Johnson or Harrison Seidner,
Ph.D.
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz
Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-announces-three-united-states-patents-for-fibroblast-technology-302057571.html
SOURCE FibroBiologics